Mineralys Therapeutics, Inc Common Stock

Yahoo Finance • 14 days ago

Mineralys outlines NDA submission timeline and advances lorundrostat trials amid expanded clinical focus

Earnings Call Insights: Mineralys Therapeutics (MLYS) Q3 2025 MANAGEMENT VIEW * Jon Congleton, President and CEO, shared that Mineralys received pre-NDA feedback from the FDA with "no surprises" and is moving ahead with its NDA filing... Full story

Yahoo Finance • 14 days ago

Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

– Submission of New Drug Application (NDA) for lorundrostat planned for late-2025/Q1 2026 – – Completed enrollment in Explore-OSA trial; topline results anticipated in Q1 2026 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa., Nov... Full story

Yahoo Finance • 14 days ago

After-Hours Earnings Report for November 10, 2025 : OXY, RKLB, ASTS, RGTI, SARO, WULF, BLTE, PLUG, MLYS, TDW, BBAI, JAMF

The following companies are expected to report earnings after hours on 11/10/2025. Visit our Earnings Calendar for a full list of expected earnings releases. Occidental Petroleum Corporation (OXY)is reporting for the quarter ending Sep... Full story

Yahoo Finance • 17 days ago

Data for Lorundrostat in Chronic Kidney Disease and Hypertension Presented at American Society of Nephrology (ASN) Kidney Week 2025

– Late-breaking presentation of Explore-CKD trial at ASN Kidney Week – – Pivotal Phase 3 Launch-HTN trial featured in the “Best of JAMA and NEJM” session - RADNOR, Pa., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Na... Full story

Yahoo Finance • last month

Mineralys Therapeutics Reaches Analyst Target Price

In recent trading, shares of Mineralys Therapeutics Inc (Symbol: MLYS) have crossed above the average analyst 12-month target price of $43.75, changing hands for $44.16/share. When a stock reaches the target an analyst has set, the analys... Full story

Yahoo Finance • 2 months ago

Stocks of possible M&A targets have been crushing the market. Goldman says these 6 are the most likely to get bought.

Mergers and acquisitions activity has surged in 2025, with a 29% increase in deal value. Goldman Sachs predicts another 15% rise in M&A deals in 2026, boosting candidate valuations. It flagged a list of firms it sees as M&A targets. Here a... Full story

Yahoo Finance • 2 months ago

Pfizer Inc. (PFE): A Bull Case Theory

We came across a bullish thesis on Pfizer Inc. on Investing With Purpose’s Substack. In this article, we will summarize the bulls’ thesis on PFE. Pfizer Inc.'s share was trading at $24.15 as of September 18th. PFE’s trailing and forward P/... Full story

Yahoo Finance • 2 months ago

These 2 Healthcare Stocks Are Up Over 100% in a Month. Can They Keep Climbing?

Key Points Shares of Nektar Therapeutics and Mineralys Therapeutics have risen sharply, and could run even further. Nektar is developing an experimental eczema treatment. Millions of patients with stubbornly high blood pressure could bene... Full story

Yahoo Finance • 2 months ago

SA Asks: Which biotechs could be acquired by year's end?

[word m and a made with wood building blocks, stock image] Maksim Labkouski The fourth quarter has historically been a busy time for the biopharma industry, with the sector generally seeing a significant uptick in M&A activity. We asked... Full story

Yahoo Finance • 3 months ago

Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need  

~Pivotal Launch-HTN trial of novel aldosterone synthase inhibitor lorundrostat enrolled a diverse range of participants with uncontrolled or resistant hypertension~ ~Subgroups - including Black or African American adults, older adults, wo... Full story

Yahoo Finance • 3 months ago

Mineralys Therapeutics Announces Closing of Upsized $287.5 Million Underwritten Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

RADNOR, Pa., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidn... Full story

Yahoo Finance • 3 months ago

Mineralys (MLYS) Steals Spotlight From AstraZeneca, Reaches Fresh Peak

We recently published 10 Power Stocks Crushing Wall Street — 7 at All-Time Highs. Mineralys Therapeutics, Inc. (NASDAQ:MLYS) is one of the best performers on Tuesday. Mineralys surged to a new all-time high on Tuesday, as investors gobble... Full story

Yahoo Finance • 3 months ago

Mineralys Therapeutics prices upsized $250M stock offering

* Mineralys Therapeutics (NASDAQ:MLYS [https://seekingalpha.com/symbol/MLYS]) priced [https://seekingalpha.com/pr/20218530-mineralys-therapeutics-announces-pricing-of-upsized-250_0-million-underwritten-public] an upsized underwritten pub... Full story

Yahoo Finance • 3 months ago

Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock

RADNOR, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidn... Full story

Yahoo Finance • 3 months ago

Mineralys Therapeutics launches $175M public offering

* Mineralys Therapeutics (NASDAQ:MLYS [https://seekingalpha.com/symbol/MLYS]) has commenced a $175M underwritten public offering of common stock. * A 30-day option allows underwriters to purchase up to an additional $26.25M in shares.... Full story

Yahoo Finance • 3 months ago

Mineralys Therapeutics Announces Proposed Public Offering of Common Stock

RADNOR, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidn... Full story

Yahoo Finance • 3 months ago

Here are the top movers in Tuesday's session.

Wondering how the US markets performed one hour before the close of the markets on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis. [topmovers] TODAY'S TOP GAINERS TICKER CHANGE COMMENT... Full story

Yahoo Finance • 3 months ago

Tuesday's ETF Movers: XBI, REMX

In trading on Tuesday, the SPDR S&P Biotech ETF is outperforming other ETFs, up about 3.2% on the day. Components of that ETF showing particular strength include shares of Mineralys Therapeutics, up about 87% and shares of Cytokinetics, u... Full story

Yahoo Finance • 3 months ago

Tuesday Sector Leaders: Precious Metals, Drugs

In trading on Tuesday, precious metals shares were relative leaders, up on the day by about 3.1%. Leading the group were shares of McEwen, up about 20% and shares of Hycroft Mining Holding up about 15.5% on the day. Also showing relative... Full story

Yahoo Finance • 3 months ago

Top movers analysis in the middle of the day on 2025-09-02: top gainers and losers in today's session.

Curious to know what's happening on the US markets in the middle of the day on Tuesday? Join us as we explore the top gainers and losers in today's session. [topmovers] GAINERS TICKER CHANGE COMMENT CARM [https://www.chartmil... Full story